Analytical and diagnostic performance of Theradiag i-Tracker assays on IDS-iSYS for infliximab and adalimumab therapeutic drug monitoring
Pauline Herroelen,Hilde Vanpoucke,Filip Baert,An-Sofie Decavele,Inge De Cuyper,Johan Debrabandere,Geert A. Martens,Dieter De Smet
DOI: https://doi.org/10.1515/cclm-2023-1432
2024-02-22
Clinical Chemistry and Laboratory Medicine (CCLM)
Abstract:Research ethics: Our study was performed according to the Helsinki Declaration, with full respect for individuals' right to confidentiality. Informed consent: Our study was performed with a waiver of informed consent, approved by the AZ Delta Ethical Committee (Clinical Trial No. IRB B1172020000008). Author contributions: The authors have accepted responsibility for the entire content of this manuscript and approved its submission. Conceptualization: PH, HV, DD. Methodology: PH, HV, DD. Validation: PH, HV, DD. Formal analysis: PH. Investigation: PH, HV, DD. Writing – original draft: PH. Writing – review and editing: HV, DD, FB, AD, ID, JD, GM. Supervision: HV, DD. Competing interests: The authors state no conflict of interest. Research funding: None declared. Data availability: The raw data can be obtained on request from the corresponding author. 1. Iijima, H, Kobayashi, T, Nagasaka, M, Shinzaki, S, Kitamura, K, Kitamura, K, et al.. Management of primary nonresponders and partial responders to tumor necrosis factor-α inhibitor induction therapy among patients with Crohn's disease. Inflamm Intest Dis 2020;5:78–83. https://doi.org/10.1159/000506337. Search in Google Scholar PubMed PubMed Central 2. Gorovits, B, Baltrukonis, DJ, Bhattacharya, I, Birchler, MA, Finco, D, Sikkema, D, et al.. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol 2018;192:348–65. https://doi.org/10.1111/cei.13112. Search in Google Scholar PubMed PubMed Central 3. Pouw, M, Krieckaert, C, Nurmohamed, M, van der Kleij, D, Aarden, L, Rispens, T, et al.. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2013;74:513–8. https://doi.org/10.1136/annrheumdis-2013-204172. Search in Google Scholar PubMed 4. Vande Casteele, N, Ferrante, M, Van Assche, G, Ballet, V, Compernolle, G, Van Steen, K, et al.. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320–9. https://doi.org/10.1053/j.gastro.2015.02.031. Search in Google Scholar PubMed 5. Schmitz, E, Van De Kerkhof, D, Hamann, D, Van Dongen, J, Kuijper, P, Brunsveld, L, et al.. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med 2016;54:1211–9. https://doi.org/10.1515/cclm-2015-0987. Search in Google Scholar PubMed 6. Van Den Bossche, D, De Smet, D, Debrabandere, J, Vanpoucke, H. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab. Clin Chem Lab Med 2019;57:856–63. https://doi.org/10.1515/cclm-2018-0891. Search in Google Scholar PubMed 7. Berger, A, Gleizes, A, Waeckel, L, Roblin, X, Krzysiek, R, Hacein-Bey-Abina, S, et al.. Validation study of a new random-access chemiluminescence immunoassay analyzer i-TRACK10 to monitor infliximab and adalimumab serum trough levels and anti-drug antibodies. Int J Mol Sci 2022;23:9561. https://doi.org/10.3390/ijms23179561. Search in Google Scholar PubMed PubMed Central 8. Rissel, F, Cazaubon, Y, Saffar, S, Altwegg, R, Artasone, M, Lozano, C, et al.. Comparative evaluation of four commercially available immunoassays for therapeutic drug monitoring of infliximab and adalimumab. Int J Mol Sci 2023;24:10379. https://doi.org/10.3390/ijms241210379. Search in Google Scholar PubMed PubMed Central 9. EMEA . Guideline on bioanalytical method validation . London, UK: European Medicines Agency; 2011. Search in Google Scholar © 2024 Walter de Gruyter GmbH, -Abstract Truncated-
medical laboratory technology